You'll notice that these two are tiny, compared to the majors. But now the series -- looking back almost five years, as to these two, is thus kept complete. [To be certain, over the past two years, Baxter's organic challenges are limiting what it spends on lobbying -- even as the 2024 election year shrank spending industry-wide.]
Hungry for more? Just use the search box, for their names -- to see the history, here. You're welcome. Heh.
. . .Baxter ($560,000):
▲ Issues related to pharmaceutical pricing. Issues related to drug shortages. Issues related to ESRD reimbursement. . . .
▲ Issues relating to drug pricing, ESRD reimbursement for Hemodialysis, 340B Drug pricing, device sterilization. Issues relating to safe mobility and issues relating to diabetic retinopathy. Issues relating to pandemic preparedness act. H. Res. 550 and H.R. 4421. Issues related to artificial intelligence technology in healthcare; issues related to Hurricane Helene, and HR 10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act 2025. . . .
▲ Issues related to increasing funding for Strategic National Stockpile. Labor, Health, and Human Services appropriations. . . .
▲Taxation of multinational companies. Monitor tax reform proposal relating to corporate tax policies. . . .
And. . . the Part II, of II:
. . .Abbott ($1,080,000):
▲ S. 2477/H.R. 1770 Equitable Community Access to Pharmacist Services Act; Proposals related to medical device cybersecurity; Proposals related to heart valve repair technologies; Proposals related to sterilization of medical devices; Proposals related to testing for malaria; Proposals related to the President's Emergency Plan for AIDS Relief (PEPFAR). . . .
▲S. 1000/H.R. 1835 Saving Access to Laboratory Services Act; H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023; Proposals related to Medicare coverage of continuous glucose monitors; Proposals to ensure Medicare coverage for emerging medical device technology; Proposals regarding PAMA regulations and changes to modernize and update the Clinical Laboratory Fee Schedule. . . .
▲ Proposals related to U.S. global health programs and pandemic preparedness; Proposals to advance global virus surveillance; Proposals regarding infant and child nutrition; Proposals related to tariffs on products imported into the United States. . . .
▲ Proposals related to access to infant formula. . . .
▲ Public Law 115-97 The Tax Cuts and Jobs Act; Public Law 117-169 Inflation Reduction Act of 2022; Proposals to reform domestic and international tax structures. . . .
You may wish to compare the above, to the series of four others (most recently) on Amgen, Pfizer, Merck and Lilly -- just look back through January archives, here.
Onward -- into a mild cloud dappled Saturday afternoon, here -- while we wait to see if Shumate decides he needs to say some more insipid, illiterate-of-US-history. . . ish -- on the purported "freeze" by his boss, Tangerine 2.0, in DC District Court, tonight. Heh.
नमस्ते
No comments:
Post a Comment